Cannabis

thcscience_admin
Not to be confused with Nephrogenic diabetes insipidus.
Central diabetes insipidus
Other namesArginine vasopressin deficiency; pituitary diabetes insipidus; neurohypophyseal diabetes insipidus; cranial diabetes insipidus; neurogenic diabetes insipidus
SpecialtyEndocrinology Edit this on Wikidata
SymptomsPolyuria, nocturia, and polydipsia.

Central diabetes insipidus, recently renamed arginine vasopressin deficiency (AVP-D),[1] is a form of diabetes insipidus that is due to a lack of vasopressin (ADH) production in the brain. Vasopressin acts to increase the volume of blood (intravascularly), and decrease the volume of urine produced. Therefore, a lack of it causes increased urine production and volume depletion.

It is also known as neurohypophyseal diabetes insipidus,[2][3] referring to the posterior pituitary (neurohypophysis), which is supplied by the hypothalamus in the brain. This condition has only polyuria in common with diabetes. Although not mutually exclusive, with most typical cases, the name diabetes insipidus is misleading.[4]

Untreated patients with central diabetes insipidus often experience polyuria, nocturia, and polydipsia due to the initial increase in serum sodium and osmolality. Central diabetes insipidus can be caused by various congenital or acquired lesions, and when the cause is unknown, it is classified as idiopathic.

The water deprivation test (WDT) is a commonly used test for diabetes insipidus, a two-step process involving parenteral desmopressin administration after an initial 8-hour water fast. It differentiates primary polydipsia from diabetes insipidus and central diabetes insipidus from nephrogenic diabetes insipidus. Diabetes insipidus is trated by restoring free water deficit, replacing the missing hormone, and addressing the underlying ailment. Desmopressin, an arginine vasopressin analog, is used to treat central diabetes insipidus.

Signs and symptoms[edit]

Untreated central diabetes insipidus patients usually exhibit polyuria, nocturia, and polydipsia as a result of the initial rise of serum sodium and osmolality.[5] Patients may also experience neurologic symptoms associated with the underlying illness, such as headaches and diplopia, depending on the exact origin of the central diabetes insipidus.[6]

Even when their polyuria and polydipsia are adequately managed, patients with central diabetes insipidus frequently suffer psychological symptoms as elevated anxiety, social isolation, and an overall lower quality of life.[7]

Causes[edit]

The clinical manifestation of central diabetes insipidus is the lack of arginine vasopressin secretion as a result of the hypothalamus/posterior pituitary axis neurons being destroyed. Numerous different congenital or acquired lesions can cause the condition.[8]

Idiopathic[edit]

When the causes of central diabetes insipidus are unknown, the condition is categorized as idiopathic.[9]

Acquired[edit]

Central diabetes insipidus is tyoically an acquired disorder.[9] The following conditions may result in central diabetes insipidus:[10]

  1. Surgery - Neurosurgery, typically in the sellar or suprasellar area, can induce central diabetes insipidus.[11] In most neurosurgery-related situations, central diabetes insipidus is temporary.[12] It is rare to have persistent postoperative central diabetes insipidus.[13]
  2. Neoplastic conditions - Central diabetes insipidus can result from primary or secondary brain malignancies that affect the hypothalamic-pituitary area; secondary tumors are typically caused by metastasis from lung or breast cancer, leukemia, or lymphoma.[14] Additionally, central diabetes insipidus is seen in myelodysplastic syndrome.[15] Craniopharyngioma, germinoma, pinealoma, glioma, and meningioma can all cause central diabetes insipidus.[10]
  3. Trauma - Central diabetes insipidus can be caused by head trauma that affects the posterior pituitary and hypothalamus.[16]
  4. Vascular disorders - Vascular disorders such as subarachnoid hemorrhage, intracranial hemorrhage, and Sheehan’s syndrome have been knwon to cause central diabetes insipidus.[10]
  5. Inflammation/Infection - Central diabetes insipidus has been linked to sarcoid, histiocytosis, granulomatosis with polyangiitis, post-tuberculosis meningitis, HIV, COVID-19, post encephalitis, toxoplasmosis, abscess, and systemic lupus erythematosus.[10]
  6. Autoimmune - It is thought that the degeneration of the hormone-secreting cells in the hypothalamus nuclei accounts for between 30 and 50 percent of nontraumatic central diabetes insipidus cases.[5] Many, if not most, of these individuals may be affected by an autoimmune process.[17][18] Pituitary stalk and posterior pituitary lymphocytic inflammation is a hallmark of the autoimmune process.[19] Lymphocytic infundibuloneurohypophysitis (LINH) is the name of the disease process that most likely explains autoimmune cases of central diabetes insipidus.[20]
  7. Pregnancy - Pregnancy can cause central diabetes insipidus due to vasopressinase enzyme.[10]
  8. Central nervous system malformation - Malformations in the central nervous system such as septo-optic dysplasia, agenesis of corpus callosum, empty sella syndrome, and pituitary hypoplasia can cause central diabetes insipidus.[10]

Genetic[edit]

Central diabetes insipidus is linked to several congenital and familial disorders. These include congenital hypopituitarism, septo-optic dysplasia, familial arginine vasopressin deficiency, Wolfram syndrome, and proprotein convertase subtilisin/kexin type 1 (PCSK1) gene deficiency.[5]

Diagnosis[edit]

Establishing whether hypotonic polyuria exists is the first stage in the diagnostic process.[8] Urine production over 50 mL/kg body weight in adults has been characterized as polyuria on 24-hour urine collection[21] and has also been arbitrarily defined as more than 3 L/day.[22]

Confounding diseases such diabetes mellitus, renal impairment, hyperglycemia, hypercalcemia, and hypokalemia should be ruled out by baseline laboratory testing once polyuria is established. Because individuals with central diabetes insipidus are more likely than those with primary polyuria to have plasma sodium concentrations at the upper end of the normal reference range, measuring ambulatory plasma sodium concentration is beneficial.[8]

The most often utilized test for diabetes insipidus is the water deprivation test (WDT). This is a two-step test where parenteral desmopressin is administered after an initial 8-hour water fast.[10] The first step is designed to differentiate primary polydipsia from diabetes insipidus. The second part of the test helps differentiate central diabetes insipidus from nephrogenic diabetes insipidus.[8]

Measurement of the arginine vasopressin responses during the intravenous infusion of hypertonic (3%–5%) sodium chloride solution can assist in differentiating between central diabetes insipidus and nephrogenic diabetes insipidus or primary polydipsia if the WDT is unable to provide a definitive diagnosis.[23]

It has been suggested to measure plasma copeptin as a stand-in for measuring plasma arginine vasopressin.[8] Measurement of thirst using an unmarked, basic 10-cm visual analogue scale has revealed that the start of thirst happens at the same osmotic threshold as arginine vasopressin secretion.[24] In patients with central diabetes insipidus, thirst responses exhibit a physiological pattern of linear rise during osmotic stimulation and reduction following water consumption.[25]

Following a diagnosis of central diabetes insipidus, MRI scanning of the hypothalamo-pituitary region is necessary to determine whether central diabetes insipidus is caused by a structural lesion.[8]

Treatment[edit]

In order to treat diabetes insipidus, the free water deficit must be restored, the missing hormone must be replaced (if central diabetes insipidus is present), and the underlying ailment must be addressed.[8] The medication desmopressin, an arginine vasopressin analogue, is used to treat central diabetes insipidus.[9]

See also[edit]

References[edit]

  1. ^ "Diabetes Insipidus is changing its name: Arginine Vasopressin Deficiency". Pituitary Foundation. 2022-11-17. Retrieved 2024-01-31.
  2. ^ Chitturi S, Harris M, Thomsett MJ, Bowling F, McGown I, Cowley D, et al. (December 2008). "Utility of AVP gene testing in familial neurohypophyseal diabetes insipidus". Clinical Endocrinology. 69 (6): 926–930. doi:10.1111/j.1365-2265.2008.03303.x. PMID 18494865. S2CID 22350358.
  3. ^ Lee YW, Lee KW, Ryu JW, Mok JO, Ki CS, Park HK, et al. (2008). "Mutation of Glu78 of the AVP-NPII gene impairs neurophysin as a carrier protein for arginine vasopressin in a family with neurohypophyseal diabetes insipidus". Annals of Clinical and Laboratory Science. 38 (1): 12–14. PMID 18316776.
  4. ^ "The Pathogenesis of Diabetes Insipidus". Journal of the American Medical Association. 49 (6): 499. 1907. doi:10.1001/jama.1907.02530060049004.
  5. ^ a b c Bichet DG, Emmett M (October 2023). Sterns RH, Christ-Crain M, Forman JP (eds.). "Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation". UpToDate. Retrieved 2024-06-23.
  6. ^ Munir G, Kusumawardani DA, Agustina H (March 2023). "Multiple intracranial metastasis from lung adenocarcinoma in a pregnant young woman: A case report". Radiology Case Reports. 18 (3). Elsevier BV: 835–839. doi:10.1016/j.radcr.2022.11.046. PMC 9793174. PMID 36582759.
  7. ^ Atila C, Loughrey PB, Garrahy A, Winzeler B, Refardt J, Gildroy P, et al. (October 2022). "Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey" (PDF). The Lancet. Diabetes & Endocrinology. 10 (10). Elsevier BV: 700–709. doi:10.1016/s2213-8587(22)00219-4. PMID 36007536.
  8. ^ a b c d e f g Garrahy A, Moran C, Thompson CJ (January 2019). "Diagnosis and management of central diabetes insipidus in adults". Clinical Endocrinology. 90 (1): 23–30. doi:10.1111/cen.13866. PMID 30269342.
  9. ^ a b c Arima H, Azuma Y, Morishita Y, Hagiwara D (December 2016). "Central diabetes insipidus". Nagoya Journal of Medical Science. 78 (4). Nagoya University School of Medicine/Graduate School of Medicine: 349–358. doi:10.18999/nagjms.78.4.349. PMC 5159460. PMID 28008190.
  10. ^ a b c d e f g Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ (September 2022). "Diagnosis and Management of Central Diabetes Insipidus in Adults". The Journal of Clinical Endocrinology and Metabolism. 107 (10). The Endocrine Society: 2701–2715. doi:10.1210/clinem/dgac381. PMC 9516129. PMID 35771962.
  11. ^ Seckl J, Dunger D (January 1989). "Postoperative diabetes insipidus". BMJ. 298 (6665): 2–3. doi:10.1136/bmj.298.6665.2. PMC 1835326. PMID 2492841.
  12. ^ Prete A, Corsello SM, Salvatori R (March 2017). "Current best practice in the management of patients after pituitary surgery". Therapeutic Advances in Endocrinology and Metabolism. 8 (3). SAGE Publications: 33–48. doi:10.1177/2042018816687240. PMC 5363454. PMID 28377801.
  13. ^ Schreckinger M, Szerlip N, Mittal S (February 2013). "Diabetes insipidus following resection of pituitary tumors". Clinical Neurology and Neurosurgery. 115 (2): 121–126. doi:10.1016/j.clineuro.2012.08.009. PMID 22921808.
  14. ^ Kimmel DW, O'Neill BP (December 1983). "Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus". Cancer. 52 (12): 2355–2358. doi:10.1002/1097-0142(19831215)52:12<2355::aid-cncr2820521232>3.0.co;2-j. PMID 6640507.
  15. ^ Sun R, Wang C, Zhong X, Wu Y (April 2016). "Diabetes Insipidus as an Initial Presentation of Myelodysplastic Syndrome: Diagnosis with Single-Nucleotide Polymorphism Array-Based Karyotyping". The Tohoku Journal of Experimental Medicine. 238 (4). Tohoku University Medical Press: 305–310. doi:10.1620/tjem.238.305. PMID 27075406.
  16. ^ Hadjizacharia P, Beale EO, Inaba K, Chan LS, Demetriades D (October 2008). "Acute diabetes insipidus in severe head injury: a prospective study". Journal of the American College of Surgeons. 207 (4). Ovid Technologies (Wolters Kluwer Health): 477–484. doi:10.1016/j.jamcollsurg.2008.04.017. PMID 18926448.
  17. ^ De Bellis A, Colao A, Di Salle F, Muccitelli VI, Iorio S, Perrino S, et al. (September 1999). "A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus". The Journal of Clinical Endocrinology and Metabolism. 84 (9). The Endocrine Society: 3047–3051. doi:10.1210/jcem.84.9.5945. PMID 10487663.
  18. ^ Pivonello R, De Bellis A, Faggiano A, Di Salle F, Petretta M, Di Somma C, et al. (April 2003). "Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology". The Journal of Clinical Endocrinology and Metabolism. 88 (4): 1629–1636. doi:10.1210/jc.2002-020791. PMID 12679449.
  19. ^ Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, Fujisawa I, et al. (September 1993). "Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus". The New England Journal of Medicine. 329 (10). Massachusetts Medical Society: 683–689. doi:10.1056/nejm199309023291002. PMID 8345854.
  20. ^ Johnston PC, Chew LS, Hamrahian AH, Kennedy L (December 2015). "Lymphocytic infundibulo-neurohypophysitis: a clinical overview". Endocrine. 50 (3). Springer Science and Business Media LLC: 531–536. doi:10.1007/s12020-015-0707-6. PMID 26219407.
  21. ^ Refardt J (September 2020). "Diagnosis and differential diagnosis of diabetes insipidus: Update". Best Practice & Research. Clinical Endocrinology & Metabolism. 34 (5): 101398. doi:10.1016/j.beem.2020.101398. PMID 32387127.
  22. ^ Christ-Crain M, Winzeler B, Refardt J (July 2021). "Diagnosis and management of diabetes insipidus for the internist: an update". Journal of Internal Medicine. 290 (1): 73–87. doi:10.1111/joim.13261. PMID 33713498.
  23. ^ Baylis PH, Cheetham T (July 1998). "Diabetes insipidus". Archives of Disease in Childhood. 79 (1). BMJ: 84–89. doi:10.1136/adc.79.1.84. PMC 1717616. PMID 9771260.
  24. ^ Thompson CJ, Bland J, Burd J, Baylis PH (December 1986). "The osmotic thresholds for thirst and vasopressin release are similar in healthy man". Clinical Science. 71 (6). London: 651–656. doi:10.1042/cs0710651. PMID 3791867.
  25. ^ Thompson CJ, Baylis PH (October 1987). "Thirst in diabetes insipidus: clinical relevance of quantitative assessment". The Quarterly Journal of Medicine. 65 (246): 853–862. PMID 3449889.

Further reading[edit]

External links[edit]

source: https://en.wikipedia.org/wiki/Neurogenic_diabetes_insipidus

Leave a Reply